Will Hemispherx Biopharma Make The Cut? (HEB)
It has been over a month since the FDA last informed Hemispherx Biopharma (AMEX:HEB) “it may require up to 1-2 additional weeks” to make its decision on HEB’s drug Ampligen, a treatment for Chronic Fatigue Syndrome. So now investors are in this state of “limbo” and no one knows when the FDA will make their decision.
According to a conference call, Dr. Carter stated Ampligen has a 80% chance of approval and possibly higher since the drug is classified as a NMW (New Molecular Entity) for which no other treatments exists. Only time will tell, until then we continue to wait.
If Ampligen is approved this will be the first and only FDA approved treatment for CFS with a estimated market of about 4 Million people.
Let us know what you think about HEB on the FavStock.com stock forums. You will notice FavStocks.com stock market forums don’t have the usual pumpers, spammers, and trolls.
You can find information about Hemispherx Biopharma (AMEX:HEB) on the links below
http://www.FavStocks.com/forum
Tags: HEB
